Advertisement

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Welcome and Introduction to Vi3C

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement

Jul

03

Today In Oncology

Real-World Heart and Lung Radiation Doses From NHS Breast Radiotherapy Plans

Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy

Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative

AACR Statement and Call to Action Concerning OMB Proposal

Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

Advertisement

© 2026 HSP News Service, L.L.C.